Louise Rodino-Klapac compensation by year
Sarepta Therapeutics Summary Compensation Table · all 5 fiscal years held| Component | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Salary | $555,577 | $616,962 | $641,063 | $666,706 | $752,505 |
| Bonus | — | — | — | $0 | $0 |
| Stock awards | $4,626,650 | $643,360 | $701,955 | $772,020 | $2,603,966 |
| Option awards | $2,959,290 | $2,263,099 | $1,988,909 | $845,250 | $822,879 |
| Non-equity incentive | $360,000 | $403,650 | $371,358 | $436,588 | $260,000 |
| Pension and deferred compensation | — | — | — | $0 | $0 |
| All other | $14,106 | $14,706 | $15,706 | $16,720 | $16,920 |
| Total | $8,515,623 | $3,941,777 | $3,718,991 | $2,737,283 | $4,456,270 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Sarepta Therapeutics, Inc. DEF 14A filed April 24, 2026, accession 0001193125-26-177247, and prior-year filings. Open the filing on EDGAR.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 93,875 | $2,020,190 | — |
| RSU | 50,000 | $1,076,000 | — |
| PSU | 16,552 | $356,199 | — |
| RSU | 8,276 | $178,100 | — |
| RSU | 8,125 | $174,850 | — |
| RSU | 4,500 | $96,840 | — |
| RSU | 2,250 | $48,420 | — |
| RSU | 2,000 | $43,040 | — |
| PSU | 1,250 | $26,900 | — |
Per the Outstanding Equity Awards at Fiscal Year-End table in Sarepta Therapeutics, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
1 Form 4 line since the FY2025 proxy (filed April 24, 2026)current to 2026-09-24 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-09-04 | Tax withholding | — | 21,423 | $22.22 | 203,900 |
The 1 most recent of 1 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Sarepta Therapeutics’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Douglas Ingram | Chief Executive Officer | $7,840,666 |
| Louise Rodino-Klapac · this page | President, Research and Development and Technical Operations | $4,456,270 |
| Ian Estepan | President, Chief Operating Officer | $4,444,392 |
| Cristin Rothfuss | Executive Vice President, General Counsel | $4,233,623 |
| Ryan Wong | Executive Vice President, Chief Financial Officer | $3,211,867 |
| Dallan Murray | Former Executive Vice President, Chief Customer Officer | $2,742,790 |
The full Sarepta Therapeutics compensation record
free company briefThis page is one person within Sarepta Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Sarepta Therapeutics's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Sarepta Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Velarion Pro: every company page, peer tools and exports, one seat